

## Appointment of Melanie Farris as Non-Executive Director

### Announcement Highlights:

- **Melanie Farris joins as independent Non-Executive Director**
- **Brings 18+ years' experience in life sciences governance, risk and financial management**
- **Will serve as Chair of the Audit and Risk Committee**

**MELBOURNE Australia, 10<sup>th</sup> April 2025:** Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company developing personalised therapies for cancer, is pleased to announce the appointment of Melanie Farris to the Board as independent Non-Executive Director.

Ms Farris brings extensive senior executive and board-level experience with prior appointments including Non-Executive Director and Company Secretary at Factor Therapeutics Limited; Non-Executive Director, Chief Financial Officer and Company Secretary at Invion Limited; and Chair of the Board of Directors of Synapse Australia Limited.

Most recently with Telix Pharmaceuticals Limited, Melanie's positions included Senior Vice President Global Governance Risk and Compliance, Chief Governance and Risk Officer and Group Company Secretary where she had responsibility for governance, risk, internal audit and sustainability frameworks, operations and compliance. Prior to her career in life sciences, Melanie was COO of the UK's FourFour Promotions Limited and Development Executive for The Prince's Foundation.

Ms Farris holds a Bachelor of Communication (Public Relations) and a Graduate Diploma in Applied Corporate Governance. She is a Fellow of the Governance Institute of Australia, a Fellow of the Chartered Governance Institute (UK) and a Graduate of the Australian Institute of Company Directors.

Prescient Chair, Dr James Campbell said: "We are pleased to welcome Melanie to the Board of Directors, especially at this exciting time for the Company. Melanie brings considerable experience in strategy, funding, governance and risk operations and oversight. Her depth of knowledge and expertise in these areas will be invaluable to the Board, shareholders and key stakeholders of Prescient. We look forward to Melanie's contribution as Prescient continues to deliver on its mission to improve outcomes for cancer patients."

Ms Farris said: “The PTX-100 Phase 1b results demonstrated strong potential to advance to market a treatment for patients with limited options. This is an exciting time for Prescient, and I look forward to contributing with my Board colleagues and the management team in building value for the Company’s stakeholders as the Phase 2 trial progresses.”

Ms Farris will serve as Chair of the Audit and Risk Committee.

### About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

### Targeted Therapy

**PTX-100:** is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas. A Phase 2 study in Cutaneous T cell lymphoma (CTCL) is planned for initiation in April 2025.

### Cell Therapy Platforms

**CellPryme-M:** Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

**CellPryme-A:** CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

**OmniCAR:** is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.



The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Find out more at [www.ptxtherapeutics.com](http://www.ptxtherapeutics.com) or connect with us via [LinkedIn](#).

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

**For more information please contact:**

Company enquiries

James McDonnell

CEO

Prescient Therapeutics

[james.mcdonnell@ptxtherapeutics.com](mailto:james.mcdonnell@ptxtherapeutics.com)

Investor enquiries

Reach Markets

1300 805 795

[ir@reachmarkets.com.au](mailto:ir@reachmarkets.com.au)

## Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

## Supplemental COVID-19 Risk Factors

Please see our website: [Supplemental COVID-19 Risk Factors](#)